Acciones de aptose biosciences inc
12/9/2019 · Learn how to read stock charts and identify technical patterns as ClayTrader does a quick stock chart review on Aptose Biosciences Inc. (APTO). 1/9/2018 · The following slide deck was published by Aptose Biosciences Inc. in conjunction with this event. Download PDF 129 Click to enlarge Notes APTO, Aptose Biosciences Inc - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Aptose Biosciences, Inc. Common Shares, also called Aptose Biosciences, is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Read More Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. 9/12/2019 · SAN DIEGO and TORONTO, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced the presentation of preclinical data for its first-in-class, FLT3/BTK inhibitor CG-806 at APTO - Aptose Biosciences, Inc. SWOT Analysis & Matrix provide insight into strategy,internal & external factors.Buy custom SWOT analysis & SWOT Matrix for $11.Strengths,Weakness Opportunities Threats
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. Business Description Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. SAN DIEGO and TORONTO, June 03, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced the closing of its previously announced underwritten public offering of 10,000,000 common shares at a price to the public of $1.85 per share, including the exercise in full by the Aptose Biosciences Inc (NASDAQ:APTO) shares have hit a new 52-week high, are up over 17%, and trading around the $2 handle in mid-afternoon trading. Real-time exchange rate quote of Aptose Biosciences, Inc. including detailed information, live chart and news, profile and other market data. 11/11/2019 · Learn how to read stock charts and identify technical patterns as ClayTrader does a quick stock chart review on Aptose Biosciences, Inc (APTO). 12/6/2019 · Since October, shares of APTOSE BIOSCIENCES INC - NASDAQ:APTO appear to be forming a rounding bottom and recently, have witnessed the recapture of its 200 DMA as well as a noticeable pick-up in volume as we can observe from the Daily chart above.
List of US stocks whose names start with A
¿Qué herramientas de análisis técnico se pueden usar para analizar APTOSE BIOSCIENCES INC? Vea diversos osciladores, medias móviles y otros indicadores técnicos Aptose Biosciences Inc. Home; About. Overview; Management Team; Board of Directors; Scientific Advisory Board
Click to news headlines for various stocks / companies in the stock market.
4 Jun 2019 SAN DIEGO and TORONTO, June 04, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, 5 Nov 2019 05, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company Encuentra la cotización más reciente, historial, noticias y otra información vital de Aptose Biosciences, Inc. (APTO) para ayudarte con tus inversiones e intercambios.
9/12/2019 · SAN DIEGO and TORONTO, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced the presentation of preclinical data for its first-in-class, FLT3/BTK inhibitor CG-806 at
Reciba gratis sus datos actualizados y en vivo para Aptose Biosciences Inc - Cotización, Acciones. Bid/Ask. 5.6700/5.6800. Símbolo. APTO. Subclase / Sector. Cotizacion de APTOSE BIOSCIENCES INC.: datos históricos y INC. 5,21 USD (+5,89%). 20/12/2019 - 12:59 15 minutos de retraso - Acciones NASDAQ Aptose Biosciences is a clinical-stage biotechnology company committed to developing first-in-class targeted agents to treat life-threatening cancers. Aptose Biosciences and CrystalGenomics Announce Issuance of European Patent for Aptose to Present at Upcoming Investor Conferences in October 2018. Aptose Biosciences, Inc. Common Shares (APTO) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. 4 Jun 2019 SAN DIEGO and TORONTO, June 04, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, 5 Nov 2019 05, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company
Reciba gratis sus datos actualizados y en vivo para Aptose Biosciences Inc - Cotización, gráficos, precios, análisis, noticias y pronósticos para APTO. ¡Entrar Ver el gráfico APTOSE BIOSCIENCES INC en directo para realizar un seguimiento de los movimientos del precio de sus acciones. Encuentre predicciones del mercado, así como noticias y datos financieros de APTO.